ClinicalTrials.gg
Active, not recruitingNCT02711553Updated Jul 22, 2026Results posted

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

A Phase 2 interventional study of Ramucirumab and Merestinib in Biliary Tract Cancer, Metastatic Cancer and Advanced Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 82 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
25th of 140
309 · median 75
Started
2016
with 5 others
Phase 2
51 of 155
9 open now
Primary completion
2018-02
later than 0 of 66 live
Registered
43rd of 155
by date
Lead sponsor
3 of 155
Eli Lilly and Company

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 25th largest by enrollment of the 140 interventional ones that give a count, is one of 6 that started in 2016, is one of 51 in phase 2, reaches primary completion later than 0 of the 66 other live ones, and was the 43rd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

03

Conditions studied

  • Biliary Tract Cancer
  • Metastatic Cancer
  • Advanced Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an performance status of 0 or 1.
  • Have a or cytologically confirmed diagnosis of non-resectable, recurrent, or biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater) .
  • Have by (RECIST).
  • Have adequate biliary drainage.
  • Have adequate organ function.
  • Males and females are sterile, , or compliant with a highly effective method.
  • Female participants of must have a negative serum pregnancy test within 7 days prior to first dose.
  • Are willing to provide blood/serum/plasma and tumor tissue samples for research purposes. Submission of blood/serum/plasma and tumor tissue samples is mandatory for participation in this study, unless restricted per local regulations.

Exclusion criteria

Exclusion Criteria:

  • Previous systemic therapy for locally advanced or disease is not allowed.
  • Have a history of or have current hepatic encephalopathy of any grade, or ascites of Grade >1, or cirrhosis with Stage B or higher.
  • Have ongoing or recent (≤6 months) hepatorenal syndrome.
  • Have had a major surgical procedure or significant traumatic injury including nonhealing wound, peptic ulcer, or bone fracture ≤28 days prior to randomization.
  • Anticipate having a major surgical procedure during the course of the study.
  • Has documented , , or uncontrolled spinal cord compression.
  • Within 6 months prior to randomization, have had any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or .
  • Have an uncontrolled arterial hypertension with systolic blood pressure ≥150 or diastolic blood pressure ≥90 millimeters of mercury (mm Hg) despite standard medical management.
  • Have a previous within 5 years of study entry or a concurrent malignancy.
  • Have a history of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
  • Have a known allergy or reaction to any of the treatment components.
  • Have a history of uncontrolled hereditary or acquired thrombotic disorder.
  • Have uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.
  • Have mixed hepatocellular biliary tract cancer histology.
  • Have a interval >470 milliseconds as calculated by the Fridericia equation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine

    Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).

    Drug: Ramucirumab · Drug: Cisplatin · Drug: Gemcitabine

  • Placebo comparator
    Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine

    Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).

    Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo IV

  • Experimental
    80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine

    Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).

    Drug: Merestinib · Drug: Cisplatin · Drug: Gemcitabine

  • Placebo comparator
    Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine

    Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).

    Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo Oral

Interventions

  • Administered IV

    Also known as: LY3009806

  • Administered orally

    Also known as: LY2801653

  • Administered IV

  • Administered IV

    Also known as: LY188011

  • DrugPlacebo Oral

    Administered orally

  • DrugPlacebo IV

    Administered IV

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)

Secondary outcomes

  1. Overall Survival (OS)

    OS defined as the time from from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: Randomization to Date of Death from Any Cause (Up To 48 Months)

  2. Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)

    ORR was the number of participants who achieve a best overall response of CR or PR divided by the total number of participants randomized to the corresponding treatment arm as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization to Disease Progression (Up To 30 Months)

  3. Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)

    Disease Control Rate (DCR) was the number of participants who achieve a best overall response of CR, PR, or SD divided by the total number of participants randomized to the corresponding treatment arm as per RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization to Disease Progression (Up To 30 Months)

  4. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

    PK was determined by the minimum observed plasma concentration (Cmin). 1 Cycle (C) = 21 days (D).

    Time frame: C1 D8, C2 D1, C3 D1, C4 D1,C5 D1,C7 D1, C9 D1 and C13 D1: Within 3 days Prior to Infusion(PTI)

  5. PK: Plasma Concentration of Merestinib

    PK was presented through graphical overlay comparison versus historic data. No numerical summary of data was intended or produced.

    Time frame: C1 D8; C2 D1; C4 D1; C6 D1; C8 D1; C2 D8; C4 D8; C6 D8; C8 D8: Morning

  6. Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

    Number of participants with positive treatment emergent anti-ramucirumab antibodies (ADA) was summarized by treatment group.

    Time frame: Predose Cycle 1 Day 1 through Follow Up (Up To 48 Months)

  7. Change From Baseline in Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)

    FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72. The Trial Outcomes Index (TOI) is the sum of the PWB, FWB and Hep subscales with a scores range of 0 to 128. The Total FACT-Hep score was the sum of all questions with a scores range of 0 to 180.Total FACT-G score was the sum of the 27 questions in the PWB, SFWB, EWB and FWB with a scores range of 0 to 108. The FACT-Hep Symptoms Index with 8 key questions and scores range of 0 to 32 from the Hep Subscale. Higher score in sub-score or total score indicates better QOL and better health state. Participants were classified as "Improved" if they had positive change from baseline, "Worsened" if they had negative change from baseline, and "Stable" otherwise.

    Time frame: Baseline, Follow Up (Up To 48 Months)

  8. Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

    EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state.

    Time frame: Baseline, Follow Up (Up To 48 Months)

  9. Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score

    EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. The second part is assessed using a VAS on which the patient rates their perceived health state, ranging from 0 millimeter (the worst health you can imagine) to 100 millimeter (the best health you can imagine).

    Time frame: Baseline, Follow Up (Up To 48 Months)

07

Results

Posted Feb 26, 2021

Participant flow

Participant flow — Overall Study
Milestone8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine
Started1065210249
Received at least 1 dose of study drug1045210248
Completed100479245
Not completed65104
Withdrew: Withdrawal by subject2110
Withdrew: Lost to follow-up3363
Withdrew: On study treatment at study conclusion1131

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
Months8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Progression Free Survival (PFS)6.47 (3.68 to 8.51)6.97 (4.34 to 9.79)6.64 (4.11 to 9.72)
Statistical analysis
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Log Rank · p = 0.4821 (p-value is 2-sided.) · Hazard ratio (hr): 1.123 · 80% CI 0.904 to 1.395Stratified by geographical region, pathological diagnosis, metastatic disease.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Log Rank · p = 0.6417 (p-value is 2-sided.) · Hazard ratio (hr): 0.920 · 80% CI 0.734 to 1.153Stratified by geographical region, pathological diagnosis, metastatic disease.
SecondaryOverall Survival (OS)

OS defined as the time from from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Time frame:
Randomization to Date of Death from Any Cause (Up To 48 Months)
Reported as:
Median · Months
Overall Survival (OS)
Months8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Overall Survival (OS)10.45 (8.48 to 11.76)14.03 (11.96 to 16.36)13.04 (11.40 to 15.31)
Statistical analysis
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Log Rank · p = 0.0870 · Hazard ratio (hr): 1.336 · 95% CI 0.959 to 1.862Stratified by geographical region, pathological diagnosis, metastatic disease.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Log Rank · p = 0.7599 · Hazard ratio (hr): 0.948 · 95% CI 0.669 to 1.342Stratified by geographical region, pathological diagnosis, metastatic disease.
SecondaryPercentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)

ORR was the number of participants who achieve a best overall response of CR or PR divided by the total number of participants randomized to the corresponding treatment arm as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization to Disease Progression (Up To 30 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)
Percentage of participants8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)31.1 (22.3 to 39.9)19.6 (11.9 to 27.3)32.7 (23.5 to 41.8)
Statistical analysis
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Exact Cochran-Mantel-Haenszel · p = 0.878 · Odds ratio (or): 1.0 · 95% CI 0.6 to 1.9Stratified by randomization strata Geographical Region, Pathological Diagnosis, Metastatic Disease.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Exact Cochran-Mantel-Haenszel · p = 0.023 · Odds ratio (or): 0.5 · 95% CI 0.2 to 0.9Stratified by randomization strata Geographical Region, Pathological Diagnosis, Metastatic Disease.
SecondaryPercentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)

Disease Control Rate (DCR) was the number of participants who achieve a best overall response of CR, PR, or SD divided by the total number of participants randomized to the corresponding treatment arm as per RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization to Disease Progression (Up To 30 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)
Percentage of participants8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)81.1 (73.7 to 88.6)83.3 (76.1 to 90.6)78.2 (70.2 to 86.3)
Statistical analysis
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Exact Cochran-Mantel-Haenszel · p = 0.680 · Odds ratio (or): 1.2 · 95% CI 0.6 to 2.4Stratified by randomization strata Geographical Region, Pathological Diagnosis, Metastatic Disease.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · Exact Cochran-Mantel-Haenszel · p = 0.499 · Odds ratio (or): 1.3 · 95% CI 0.6 to 2.6Stratified by randomization strata Geographical Region, Pathological Diagnosis, Metastatic Disease.
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

PK was determined by the minimum observed plasma concentration (Cmin). 1 Cycle (C) = 21 days (D).

Time frame:
C1 D8, C2 D1, C3 D1, C4 D1,C5 D1,C7 D1, C9 D1 and C13 D1: Within 3 days Prior to Infusion(PTI)
Reported as:
Geometric mean · Microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
Microgram per milliliter (µg/mL)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine
Cycle 1 Day 8 (Week 1)46.2 ± 32
Cycle 2 Day 1 (Week 3)38.1 ± 42
Cycle 3 Day 1 (Week 6)54.1 ± 43
Cycle 4 Day 1 (Week 9)77.3 ± 50
Cycle 5 Day 1 (Week 12)82.9 ± 35
Cycle 7 Day 1 (Week 18)85.6 ± 39
Cycle 9 Day 1 (Week 24)82.7 ± 35
Cycle 13 Day 1 (Week 36)97.7 ± 23
SecondaryPK: Plasma Concentration of Merestinib

PK was presented through graphical overlay comparison versus historic data. No numerical summary of data was intended or produced.

Time frame:
C1 D8; C2 D1; C4 D1; C6 D1; C8 D1; C2 D8; C4 D8; C6 D8; C8 D8: Morning

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

Number of participants with positive treatment emergent anti-ramucirumab antibodies (ADA) was summarized by treatment group.

Time frame:
Predose Cycle 1 Day 1 through Follow Up (Up To 48 Months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
Participants8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine
Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies30
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)

FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72. The Trial Outcomes Index (TOI) is the sum of the PWB, FWB and Hep subscales with a scores range of 0 to 128. The Total FACT-Hep score was the sum of all questions with a scores range of 0 to 180.Total FACT-G score was the sum of the 27 questions in the PWB, SFWB, EWB and FWB with a scores range of 0 to 108. The FACT-Hep Symptoms Index with 8 key questions and scores range of 0 to 32 from the Hep Subscale. Higher score in sub-score or total score indicates better QOL and better health state. Participants were classified as "Improved" if they had positive change from baseline, "Worsened" if they had negative change from baseline, and "Stable" otherwise.

Time frame:
Baseline, Follow Up (Up To 48 Months)
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)
Units on a Scale8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
PWB-2.75 ± 0.43-2.88 ± 0.43-1.65 ± 0.42
SWB-0.26 ± 0.360.22 ± 0.360.56 ± 0.36
EWB0.23 ± 0.310.64 ± 0.320.93 ± 0.31
FWB-2.40 ± 0.44-1.34 ± 0.44-0.75 ± 0.44
HCS-3.62 ± 0.63-2.32 ± 0.64-0.68 ± 0.63
FACT-Hep-1.11 ± 0.37-0.74 ± 0.37-0.09 ± 0.37
TOI-8.68 ± 1.31-6.43 ± 1.32-3.01 ± 1.30
Statistical analysis
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.069 (p-values are from Type 3 sums of squares mixed model repeated measures (MMRM) Model.) · Ls mean difference: -1.10 · 95% CI -2.28 to 0.09Least Squares (LS) Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.042 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -1.23 · 95% CI -2.42 to -0.04LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine · MMRM Model · p = 0.112 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.82 · 95% CI -1.83 to 0.19LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.505 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.34 · 95% CI -1.35 to 0.67LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.116 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.70 · 95% CI -1.56 to 0.17LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.521 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.29 · 95% CI -1.16 to 0.59LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.008 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -1.66 · 95% CI -2.87 to -0.44LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.335 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.60 · 95% CI -1.82 to 0.62LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.001 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -2.93 · 95% CI -4.69 to -1.18LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.068 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -1.64 · 95% CI -3.40 to 0.12LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.051 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -1.02 · 95% CI -2.04 to 0.00LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.212 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -0.65 · 95% CI -1.68 to 0.38LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.002 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -5.67 · 95% CI -9.30 to -2.04LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
  • 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Pooled Placebo · MMRM Model · p = 0.066 (p-values are from type 3 sums of squares MMRM model.) · Ls mean difference: -3.42 · 95% CI -7.07 to 0.22LS Mean value was adjusted for treatment, visit, baseline, treatment\*visit and baseline\*visit.
SecondaryChange From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state.

Time frame:
Baseline, Follow Up (Up To 48 Months)
Reported as:
Mean · Units on a Scale
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
Units on a Scale8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score0.61 ± 0.310.63 ± 0.290.66 ± 0.27
SecondaryChange From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score

EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. The second part is assessed using a VAS on which the patient rates their perceived health state, ranging from 0 millimeter (the worst health you can imagine) to 100 millimeter (the best health you can imagine).

Time frame:
Baseline, Follow Up (Up To 48 Months)
Reported as:
Mean · millimeter (mm)
Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score
millimeter (mm)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePooled Placebo
Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score66.44 ± 22.866.57 ± 21.7369.08 ± 20.03

Adverse events

Collected over Randomization Up To 48 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine84/104 (80.8%)53/104 (51%)102/104 (98.1%)
Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine34/52 (65.4%)25/52 (48.1%)49/52 (94.2%)
80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine71/102 (69.6%)56/102 (54.9%)100/102 (98%)
Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine38/48 (79.2%)23/48 (47.9%)48/48 (100%)
Most frequent serious events
Showing 10 of 154
Most frequent serious events
Event8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine
ThrombocytopeniaBlood and lymphatic system disorders6/1043/522/1023/48
Atrial fibrillationCardiac disorders0/1043/520/1020/48
NeutropeniaBlood and lymphatic system disorders3/1041/525/1020/48
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1040/525/1021/48
PyrexiaGeneral disorders5/1041/524/1022/48
CholangitisHepatobiliary disorders5/1040/522/1021/48
Febrile neutropeniaBlood and lymphatic system disorders1/1042/521/1022/48
AscitesGastrointestinal disorders3/1040/522/1022/48
Jaundice cholestaticHepatobiliary disorders1/1040/520/1022/48
Acute kidney injuryRenal and urinary disorders2/1040/523/1022/48
Most frequent other events
Showing 10 of 463
Most frequent other events
Event8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine
NeutropeniaBlood and lymphatic system disorders63/10424/5252/10219/48
FatigueGeneral disorders61/10417/5253/10222/48
NauseaGastrointestinal disorders52/10421/5258/10215/48
ThrombocytopeniaBlood and lymphatic system disorders56/10415/5242/10215/48
AnemiaBlood and lymphatic system disorders52/10422/5240/10224/48
Abdominal painGastrointestinal disorders39/10413/5233/10215/48
Decreased appetiteMetabolism and nutrition disorders39/10414/5226/10214/48
ConstipationGastrointestinal disorders33/10414/5236/10213/48
VomitingGastrointestinal disorders34/10412/5234/10212/48
DiarrhoeaGastrointestinal disorders34/1049/5229/1027/48

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabineTotal
Mean63.49 ± 9.7657.06 ± 11.6760.95 ± 9.1462.00 ± 9.1461.33 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabineTotal
All randomized participants — Female60265422162
All randomized participants — Male46264827147
All randomized participants who received at least 1 dose of study drug — Female59265421160
All randomized participants who received at least 1 dose of study drug — Male45264827146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabineTotal
Hispanic or Latino00000
Not Hispanic or Latino00000
Unknown or Not Reported1065210249309
Race (NIH/OMB)
Race (NIH/OMB)(Participants)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabineTotal
American Indian or Alaska Native00101
Asian201126966
Native Hawaiian or Other Pacific Islander00000
Black or African American11114
White78357038221
More than one race00000
Unknown or Not Reported754117
Region of Enrollment
Region of Enrollment(Participants)8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabinePlacebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² GemcitabineTotal
Argentina1138325
Hungary574117
United States1236425
Czechia225211
United Kingdom425314
Russia924621
Spain8310122
Austria32106
South Korea8612430
Sweden10326
Turkey677323
Belgium613414
Taiwan9513431
Denmark11316
Mexico40307
Australia622414
France855220
Germany318517
08

Study locations

82 sites
09

References and documents

Publications

  • Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan AC, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely SC, Moser BA, Oliveira JM, Carlesi R, Walgren RA, Oh DY. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1468-1482. doi: 10.1016/S1470-2045(21)00409-5. PubMed 34592180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Feb 2018, 20 months.

Results were first posted in Feb 2021, 3 years after primary completion. A results delay was requested in Feb 2019.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Mar 17, 2016
StartActual
May 19, 2016
Primary completionActual
Feb 16, 2018
CompletionEst.
Dec 2026
Results delay requested
Feb 8, 2019
Results first posted
Feb 26, 2021
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02711553
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
May 19, 2016
Primary completion
Feb 16, 2018
Completion
Dec 2026 (estimated)
Results posted
Feb 26, 2021
Last update
Jul 22, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Merestinib

Start the discussion